Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AIMP2 | Q13155 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 11/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30597934 | 1.00 | AIMP2 (0.55) | AIMP2MEN1KMT2ACTSSCYP3A4 | |
| SCHEMBL1954172 | 0.85 | MMP1 (0.48) | AIMP2MEN1KMT2ATSHR | |
| SCHEMBL22500236 | 0.82 | CCR1 (0.62) | AIMP2MEN1KMT2ACTSSTSHR | |
| SCHEMBL15254954 | 0.81 | CCR1 (0.41) | AIMP2MEN1KMT2ACTSSGAA | |
| SCHEMBL3493975 | 0.81 | HTT (0.42) | AIMP2MEN1KMT2ACTSSCYP3A4 | |
| SCHEMBL8307745 | 0.80 | CTSK (0.60) | AIMP2MEN1KMT2ACTSSTSHR | |
| SCHEMBL22591021 | 0.80 | CTSK (0.60) | AIMP2MEN1KMT2ACTSSTSHR | |
| SCHEMBL19853291 | 0.80 | CTSK (0.60) | AIMP2MEN1KMT2ACTSSTSHR | |
| SCHEMBL7360133 | 0.80 | AIMP2 (0.47) | AIMP2MEN1KMT2ACTSSCYP3A4 | |
| SCHEMBL10859609 | 0.80 | KDM4E (0.47) | CYP2C19GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | AMGEN INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3494108-B1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3494108-A1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Amgen Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018027021-A1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284617-A1 | Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof | EPOR, KDM5A, PSMA5 | AIMP2 1713/4885MEN1 887/4885KMT2A 98/4885 |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | EPOR, KDM5A, PSMA5 | AIMP2 1713/4885MEN1 887/4885KMT2A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.